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The efficacy of drug-eluting stents (DES) has been known to be influenced by the
drug delivery platform (stent design and polymer), drug, and its dose.
1-5 Some
studies have reported that a considerable variation of the drug concentration in the
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Purpose: Previous studies suggested that asymmetric stent expansion did not
affect suppression of neointimal hyperplasia (NIH) after sirolimus-eluting stents
(SES) implantation. The aim of this study was to evaluate the effects of stent
eccentricity (SE) on NIH between SES versus paclitaxel-eluting stents (PES)
using an intravascular ultrasound (IVUS) analysis from the randomized trial.
Materials and Methods: Serial IVUS data were obtained from Post-stent Opti-
mal Expansion (POET) trial, allocated randomly to SES or PES. Three different
SE (minimum stent diameter divided by maximum stent diameter) were evaluat-
ed; SE at the lesion site with maximal %NIH area (SE-NIH), SE at the minimal
stent CSA [SE-minimal stent area (SE-MSA)], and averaged SE through the entire
stent (SE-mean). We classified each drug-eluting stents (DES) into the concentric
(≥ mean SE) and eccentric groups (< mean SE) based on the mean value of SE.
Results: Among 301 enrolled patients, 233 patients [SES (n = 108), PES (n =
125)] underwent a follow-up IVUS. There was no significant correlation between
%NIH area and SE-NIH (r = - 0.083, p = 0.391) or SE-MSA (r = - 0.109, p =
0.259) of SES. However, SE-NIH of PES showed a weak but significant correla-
tion with %NIH area (r = 0.269, p < 0.01). As to the associations between SE-
mean and NIH volume index, SES revealed no significant correlation (r = - 0.001,
p = 0.990), but PES showed a weak but significant correlation (r = 0.320, p <
0.01). However, there was no difference in the restenosis rate between the eccen-
tric versus concentric groups of both DES. Conclusion: This study suggests that
lower SE of both SES and PES, which means asymmetric stent expansion, may
not be associated with increased NIH.
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arterial wall is present after DES implantation.
3,4 Thereaf-
ter, the asymmetric stent expansion or strut distribution has
been regarded as potential factors for the significant neoin-
timal growth after DES implantation. However, in the
recent intravascular ultrasound (IVUS) substudy of the
SIRolImUScoated Bx Velocity stent in the treatment of
patients with de novo coronary artery lesions (SIRIUS)
trial,
6 asymmetric stent expansion after sirolimus-eluting
stents (SES) implantation did not affect suppression of
neointimal hyperplasia (NIH).
7 However, until now, there
were no data regarding asymmetric stent expansion of
paclitaxel-eluting stents (PES), those relations with NIH,
and comparative data regarding the effect of stent eccen-
tricity (SE) on NIH between SES versus PES. Therefore,
the aim of this study is to evaluate the significance of DES
eccentricity according to the types of DES through a serial
follow-up IVUS study.
Study population
This study represents an IVUS substudy of Post-stent Opti-
mal Stent Expansion (POET) trial, the prospective, multi-
center, 2×2 randomized study comparing the efficacy
according to the types of balloons (non-compliant versus
compliant balloon) and types of DES [PES (Taxus Ex-
press
TM, Boston Scientific, Natick, MA, USA) versus SES
(Cypher Bx-Velocity
®, Cordis Corp, Miami Lakes, Florida,
USA)] in de novo native coronary lesions.
8 A serial IVUS
evaluation was performed at each step; baseline, post-
procedural IVUS until optimal stent expansion criteria
were met,
9 and the 9-month follow-up IVUS. Patients were
eligible if they had a de novo target lesion of a native coro-
nary artery with a reference vessel diameter (RVD) of 2.5
to 3.5 mm that could be covered by a single stent. The more
precise explanations regarding rationale and design of the
POET trial have been previously presented.
8 Among the
301 patients originally enrolled in this study (152 PES and
149 SES), the follow-up IVUS at 9 months was performed
in 233 patients [SES group (n = 108) versus PES group (n
= 125)]. These patients with the IVUS follow-up comprised
the subjects of the present study. 
Quantitative angiographic analysis
Quantitative coronary angiography (QCA) was performed
using an offline QCA system (CMS, Medis Medical Imag-
ing System, Nuenen, The Netherlands) by a single individ-
ual who was blinded to a patient’s treatment assignment in
an independent core laboratory at Yonsei University Medi-
cal Center (Cardiovascular Research Center, Seoul, Korea).
Using the guiding catheter for magnification-calibration,
minimal luminal diameter (MLD) and diameters of the
reference segments were measured before and after stenting
from diastolic frames in a single, matched view showing
the smallest MLD. The RVD was the average of the proxi-
mal and distal reference lumen diameters. Late loss was
defined as the difference between the MLD at follow-up
and the MLD post-procedure. Angiographic restenosis was
defined as ≥ 50% luminal narrowing at the treated lesion
or the in-segment lesion within 10 mm in the 9-month
follow-up angiography.
IVUS assessment
All IVUS images were reviewed in an independent IVUS
core laboratory at Yonsei University Medical Center. IVUS
assessment was performed using a commercially available
IVUS system (Boston Scientific/Scimed, Natick, Massa-
chusetts, USA) with automatic motorized 0.5 mm/s pull-
back. Studies were recorded on s-VHS tape or compact
disk for offline analysis using the EchoPlaque 2 system
(INDEC Systems, Inc., Mountain View, California, USA).
Proximal reference cross-sectional area (CSA) and distal
reference CSA were measured at the most visually normal
area (largest lumen with the least plaque burden) within 10
mm of the proximal or distal ends of the lesion. Minimal
luminal CSA was defined as the smallest area within the
target lesion. Minimal stent CSA [minimal stent area
(MSA)] was taken as the smallest area within the stent. The
%NIH area was defined as NIH area (stent CSA minus
lumen CSA) divided by stent CSA. The stent volume,
lumen volume, and NIH volume (stent volume minus lumen
volume) was analyzed, using Simpson’s method. NIH
volume index was calculated as NIH volume divided by
the length of stent. 
SE was defined as minimum stent diameter divided by
maximum stent diameter. We investigated three different
SE parameters defined as follows: 1) SE determined at the
lesion site with maximal %NIH area on follow-up IVUS
(SE-NIH) (Fig. 1A), 2) SE determined at the site with MSA
(SE-MSA) (Fig. 1B), and 3) mean SE (SE-mean) was the
averaged value through the entire stent (Fig. 1C). For the
evaluation of the association between different SE parame-
ters of each DES and angiographic or clinical outcomes,
we re-divided each DES group into the two groups based
on the mean value of SE; the concentric (≥ mean SE) and
eccentric expansion groups (< mean SE). 
Statistical analysis
Statistical analysis was performed with SPSS software,
version 13.0 (SPSS Inc, Chicago, IL, USA). Categorical
data were presented as frequencies and compared with
Chi-square statistics or Fisher’s exact test. Continuous data
were presented as mean ± 1SD and compared with Student
MATERIALS AND METHODSt-test. Correlations between SE and %NIH area or NIH
volume index were tested with Pearson’s univariate test.
To determine the independent predictors for the angiogra-
phic restenosis in the total population, multivariate logistic
regression analysis was performed, and variables that were
predictive at the 0.1 level by univariate analysis were enter-
ed into final multivariate analysis. A value of p < 0.05 de-
noted statistical significance.
Comparison of SE and baseline characteristics 
according to the different determinations of SE 
between SES versus PES
There were no significant differences of the baseline clinical,
angiographic, and procedural characteristics and IVUS
parameters between the SES versus PES group or compli-
ant versus non-compliant postdilation balloon, as previou-
sly presented.
8
The comparison of different SE parameters between SES
and PES was presented in Table 1. The SE-NIH and SE-
mean of the PES group were significantly higher than that
of the SES group. However, the absolute difference of SE
between the two groups was minimal (mean difference
0.01). There was no significant difference in SE-MSA
between the two groups.
Each DES group was divided into the concentric and the
eccentric stent expansion subgroup and baseline charac-
teristics of each subgroup were compared in Table 2. The
patients in the concentric stent expansion subgroup of SES
according to the SE-NIH were more likely to have an acute
coronary syndrome as an initial presentation, compared
with the eccentric group of SES by SE-NIH (49% versus
29%, p = 0.032). The eccentric group of SES according to
SE-MSA showed a longer lesion length (22.9 ± 7.4 mm)
than that of the concentric group of SES (19.1 ± 6.0 mm,
p = 0.005). There was no significant difference of the
baseline characteristics in the PES group. In addition, there
were no significant differences in the other baseline char-
acteristics between the two groups.
Associations between SE parameters and NIH
There was no significant correlation between %NIH area
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Table 1. Comparison of Different SE 
SES group (n = 108) PES group (n = 125) pvalue
SE-NIH 0.89 ± 0.04 0.90 ± 0.04 0.027
SE-MSA 0.88 ± 0.05 0.88 ± 0.04 0.776
SE-mean 0.89 ± 0.03 0.90 ± 0.02 0.025
Values are presented as mean ±SD.
SE, stent eccentricity; SES, sirolimus-eluting stents; PES, paclitayel-eluting stents; NIH, neointimal hyperplasia; MSA, minimal stent area.
Fig. 1. Schematic examples of three different determinations of stent eccen-
tricity (SE). SE is defined as minimum stent diameter (D1) divided by maximum
stent diameter (D1’). Outer lager circle and smaller circle on each slice mean
EEM and stent CSA, respectively. (A) SE-NIH was determined at the lesion site
with maximal %NIH area on the follow-up IVUS. (B) SE-MSA was determined
at the site with MSA. (C) SE-mean was determined by the averaged SE through
the entire stent at the interval of 1 mm. EEM, external elastic membrane; CSA,
cross-sectional area; NIH, neointimal hyperplasia; MSA,  minimal stent area. 
RESULTS
SE-NIH
SE-NIH = D1/D1’
SE-MSA
SE-MSA = D1/D1’
SE-mean
n = No of calculated slices
SE-mean = Σ
(SE1+SE2+...+SEn)
n
A
B
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Table 2.Baseline Characteristics of Each Group
SES (n = 108) PES (n = 125)
SE-NIH
Concentric Eccentric 
pvalue
Concentric Eccentric 
pvalue
(n = 59) (n = 49) (n = 71) (n = 54)
Age (yrs) 59 ± 8  62 ± 11  0.207  63 ± 9  62 ± 9  0.675 
Men, n (%) 21 (36)  18 (37)  1.000  34 (48)  21 (39)  0.365 
Hypertension (%) 39 (66)  34 (69)  1.000  46 (65)  34 (63)  1.000 
Smokers, n (%) 19 (32)  9 (19)  0.069  10 (14)  10 (19)  0.624 
Diabetes, n (%)  23 (39)  11 (22)  0.095  19 (27)  19 (35)  0.332 
Hyperlipidemia, n (%) 8 (14)  9 (19)  0.598  20 (28)  12 (22)  0.537 
Previous MI, n (%) 6 (10)  3 (6)  0.285  2 (3)  5 (9)  0.136 
ACS presented, n (%) 29 (49)  14 (29)  0.032  26 (37)  23 (43)  0.464 
LAD treated, n (%) 36 (61) 35 (71) 0.514 41 (58) 37 (67) 0.353
RVD, mm 3.06 ± 0.39 3.06 ± 0.42 0.955  2.97 ± 0.40 3.00 ± 0.43 0.708 
Lesion length, mm 20.3 ± 6.5  21.2 ± 7.3  0.497  21.3 ± 6.1  21.8 ± 7.4  0.666
Type B2/C, n (%) 42 (71) 35 (71) 1.000  56 (79)  37 (69)  0.218 
Stent diameter, mm 3.19 ± 0.28  3.25 ± 0.30  0.289  3.20 ± 0.33  3.21 ± 0.27  0.839 
Stent length, mm 23.8 ± 5.1  24.0 ± 6.2  0.874  25.3 ± 5.6  24.3 ± 4.9  0.319 
Use of NC balloon, n (%) 33 (56)  23 (47)  0.440  35 (49)  29 (54)  0.718 
Postprocedural MLD, mm 2.97 ± 0.31  2.96 ± 0.40  0.836  2.63 ± 0.39  2.62 ± 0.45  0.885 
SE-MSA
Concentric Eccentric
pvalue
Concentric Eccentric 
pvalue
(n = 63) (n = 45) (n = 73) (n = 52)
Age (yrs) 58 ± 10  61 ± 9  0.385  62 ± 9  63 ± 9  0.632 
Men, n (%) 22 (35)  17 (38)  0.840  34 (47)  21 (40)  0.584 
Diabetes, n (%)  18 (29)  16 (36)  0.530  22 (30)  16 (31)  1.000 
ACS presented, n (%) 26 (41)  17 (38)  0.842  27 (37)  22 (42)  0.576 
RVD, mm 3.08 ± 0.42  3.02 ± 0.38  0.410  3.02 ± 0.43  2.93 ± 0.39  0.236 
Lesion length, mm 19.1 ± 6.0  22.9 ± 7.4  0.005  21.5 ± 7.2  21.5 ± 5.8  0.991 
Stent diameter, mm 3.22 ± 0.28  3.22 ± 0.30  0.978  3.22 ± 0.29  3.17 ± 0.32  0.369 
Stent length, mm 23.2 ± 5.2  25.0 ± 6.1  0.092  25.0 ± 5.2  24.8 ± 5.6  0.845 
Use of NC balloon, n (%) 39 (62)  17 (38)  0.019  35 (48)  29 (56)  0.468 
Postprocedural MLD, mm 2.98 ± 0.34  2.95 ± 0.38  0.687  2.65 ± 0.40  2.58 ± 0.44  0.389 
SE-mean
Concentric Eccentric
pvalue
Concentric Eccentric 
pvalue
(n = 63) (n = 45) (n = 67) (n = 58)
Age (yrs) 60 ± 10 62 ± 9  0.234  63 ± 9  62 ± 9  0.873 
Men, n (%) 20 (32) 19 (42)  0.312  33 (49)  22 (38)  0.213 
Diabetes, n (%)  22 (35) 12 (27)  0.406  24 (36)  14 (24)  0.176 
ACS presented, n (%) 29 (46)  14 (31)  0.163  23 (35)  26 (45)  0.275 
RVD, mm 3.08 ± 0.42  3.03 ± 0.39  0.586  2.93 ± 0.41  3.04 ± 0.41  0.157 
Lesion length, mm 20.2 ± 6.3  21.4 ± 7.6  0.378  21.5 ± 7.2  21.5 ± 6.0  0.964 
Stent diameter, mm 3.17 ± 0.29  3.28 ± 0.28  0.066  3.16 ± 0.31  3.25 ± 0.29  0.133 
Stent length, mm 23.8 ± 5.5 24.1 ± 5.8  0.773  24.9 ± 5.5  24.8 ± 5.1  0.919 
Use of NC balloon, n (%) 31 (49) 25 (56)  0.562  32 (48)  32 (55)  0.474 
Postprocedural MLD, mm 2.98 ± 0.33 2.95 ± 0.39  0.728  2.92 ± 0.39  2.89 ± 0.41  0.718 
SES, sirolimus-eluting stents; PES, paclitaxel-eluting stents; SE, stent eccentricity; NIH, neointimal hyperplasia; MI, myocardial infarction; ACS, acute coronary 
syndrome; LAD, left anterior descending artery; RVD, reference vessel diameter; MLD, minimal lumen diameter; MSA, minimal stent area; NC, non-compliant.and SE-NIH of the SES group (r = - 0.083, p = 0.391; see)
(Fig. 2A). However, in cases of PES, SE-NIH showed a
weak but significant correlation with %NIH area, which
meant that a higher SE caused slightly more NIH (r = 0.269,
p < 0.01). Between SE-MSA and %NIH area, there was no
significant correlation in both the SES and PES groups
(Fig. 2B). 
As to the associations between SE-mean and NIH vol-
ume index, the SES group revealed no significant correla-
tion (r = - 0.001, p = 0.990), but the PES group showed a
weak but significant correlation (r = 0.320, p < 0.01),
similar to SE-NIH (Fig. 2C).
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Fig. 2. Association between three different SEs and neointimal hyperplasia. (A) Correlation between SE-NIH (determined at the narrowest portion
with large NIH on follow-up IVUS) and %NIH area. (B) Correlation between SE-MSA (determined at the site with minimal stent CSA) and %NIH
area. (C) Correlation between mean SE (averaged value through the entire stent) and NIH volume index. SE, stent eccentricity; NIH, neointimal
hyperplasia; IVUS, intravascular ultrasound; MSA, minimal stent area; CSA, cross-sectional area.
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outcomes
Follow-up angiographic and IVUS outcomes of each
expansion group were compared in Table 3. The SES group
showed that there were no significant differences in the
late loss, restenosis rate, and %NIH area between the con-
centric versus eccentric expansion groups defined by 3 dif-
ferent SE parameters. However, the concentric stent expan-
sion subgroup of PES according to SE-NIH showed a
significant trend toward having a larger %NIH (39 ± 21
versus 32 ± 21%, p = 0.06) (Table 3). In addition, the con-
centric stent expansion subgroup of PES according to SE-
mean had a significantly higher NIH volume index (1.26 ±
1.08 versus 0.73 ± 0.79 mm
2, p= 0.003) (Table 3).
As to the associations between each group according to
the expansion of DES and each clinical outcome, there
was no significant difference in the rate of death, myocar-
dial infarction, target-lesion revascularization (TLR), or
stent thrombosis between the concentric and eccentric stent
expansion subgroups of each DES (Table 4). 
Multivariate analysis of predictors for the 
angiographic restenosis
Using multivariate logistic analysis, the significant inde-
pendent predictors for the angiographic restenosis from the
total population of our study were the use of PES [odds
ratio (OR): 8.25, 95% CI: 1.79-37.99] and the presence of
diabetes (OR: 3.4, 95% CI: 1.0-11.3). Other parameters
including SE were not significant predictors for the angio-
graphic restenosis.
This study demonstrated SE of PES was significantly
higher than that of SES, which meant that PES showed
more symmetric expansion with high-pressure post-dila-
tion than SES. However, there were no consistent correla-
Byeong-Keuk Kim, et al.
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DISCUSSION
Table 3.Follow-Up Angiographic and IVUS Characteristics
SES (n = 108) PES (n = 125)
SE-NIH
Concentric Eccentric
pvalue
Concentric Eccentric 
pvalue
(n = 59) (n = 49) (n = 71) (n = 54)
RVD, mm 2.91 ± 0.35 2.94 ± 0.38 0.717  2.88 ± 0.42 2.92 ± 0.40 0.621 
MLD, mm 2.74 ± 0.44 2.63 ± 0.45 0.204  2.25 ± 0.75  2.34 ± 0.71  0.471 
Late loss, mm 0.23 ± 0.40  0.33 ± 0.46  0.261 0.65 ± 0.69  0.54 ± 0.63  0.369
Restenosis, n (%) 2 (3) 2 (4) 1.00 9 (13) 8 (15) 0.80
MSA, mm
2 6.11 ± 1.32  5.96 ± 1.65  0.606  6.02 ± 1.55  6.19 ± 1.44  0.519 
%NIH area 10 ± 13 15 ± 13 0.08 39 ± 21 32 ± 21 0.06
SE-MSA
Concentric Eccentric
pvalue
Concentric Eccentric 
pvalue
(n = 63) (n = 45) (n = 73) (n = 52)
RVD, mm 2.93 ± 0.37 2.91 ± 0.35 0.702  2.91 ± 0.41 2.65 ± 0.45 0.686 
MLD, mm 2.70 ± 0.47 2.68 ± 0.42 0.849  2.29 ± 0.77 2.29 ± 0.68 0.978 
Late loss, mm 0.28 ± 0.46 0.27 ± 0.38 0.906  0.63 °æ0.73 0.57 ± 0.56 0.643
Restenosis, n (%) 4 (6)  0 (0)  0.139 10 (14) 7 (14) 1.000
MSA, mm
2 6.10 ± 1.44  5.82 ± 1.51  0.224  6.19 ± 1.52  5.94 ± 1.47  0.326 
%NIH area 0.9 ± 3.3  1.5 ± 5.0  0.439  9.1 ± 16.0  5.6 ± 14.3  0.212 
SE-mean
Concentric Eccentric 
pvalue
Concentric Eccentric 
pvalue
(n = 63) (n = 45) (n = 67) (n = 58)
RVD, mm 2.93 ± 0.38  2.91 ± 0.33  0.859  2.83 ± 0.38  2.97 ± 0.43  0.067 
MLD, mm 2.68 ± 0.49  2.71 ± 0.39  0.749  2.19 ± 0.74  2.39 ± 0.72  0.129 
Late loss, mm 0.30 ± 0.43  0.25 ± 0.43  0.526 0.70 ± 0.73  0.50 ± 0.55  0.088
Restenosis, n (%) 3 (5)  1 (2)  0.639 13 (19)  4 (7)  0.065
MSA, mm
2 6.12 ± 1.45  5.93 ± 1.52  0.513  5.87 ± 1.49  6.36 ± 1.48  0.071 
NIH volume index, mm
2 0.19 ± 0.32  0.23 ± 0.43  0.594  1.26 ± 1.08  0.73 ± 0.79  0.003 
%NIH obstruction 2.91 ± 5.07  3.47 ± 6.12  0.611  17.23 ± 14.51  9.67 ± 10.52  0.002 
Values are presented as mean ±SD or numbers (percentages).
IVUS, intravascular ultrasound; VUS, intravascular ultrasound; SES, sirolimus-eluting stents; PES, paclitaxel-eluting stents; SE, stent eccentricity; NIH, neointimal
hyperplasia; RVD, reference vessel diameter; MLD, minimal lumen diameter; MSA, minimal stent area.tions between SE according to the various determinations
and neointimal growth of both the SES and PES groups. In
addition, there were no correlations between the degree of
SE and clinical outcomes such as restenosis, TLR, or stent
thrombosis. 
The DES eccentricity had been previously considered as
one of the IVUS predictors for restenosis, because of the
higher possibility of the uneven diffusion of  the drug into
the arterial wall due to asymmetric stent expansion.
3,4,7
However, recent reports showed that SE of SES did not
affect NIH.
4,10 The powerful effect of NIH suppression by
SES could overcome the uneven diffusion of the drug into
the vessel wall from the SE. Based on these studies, Dr.
Mintz GS and Weissman NJ concluded that SES asym-
metry has no clinical impact.
11
The present study focused on several issues that were
not evaluated in previous studies. First, we investigated the
impact of local SE parameters on neointimal growth at the
same location. The SIRIUS IVUS sub-study used only the
mean SE. Therefore, it was not certain whether focal SE
within a stent has any effect on NIH.
4,10 We investigated
not only the mean SE through the entire stent but also SE
of two specific portions: the lesion site with maximal
%NIH area on the follow-up IVUS and the site with MSA,
in which SE might contribute to more neointimal growth
after stent implantation. Secondly, there were no data re-
garding the impact of SE in cases of PES, which has a
different drug and different design of stent platform, com-
pared with SES. Third, we directly compared SES and
PES for asymmetry of stent expansion and its impact on
neointimal growth and clinical outcomes from the rando-
mized trial. 
This study confirms the previous finding that eccentri-
city of stent expansion in the SES group has no impact on
neointimal growth and clinical outcomes such as death,
myocardial infarction (MI), target-lesion revascularization
(TLR), or stent thrombosis. PES showed slightly more
symmetric expansion compared to SES. However, against
our expectations, more symmetric stent expansion in the
PES group was rather associated with greater neointimal
growth, even though this association had no clinical signi-
ficance. This association might be explained by different
baseline characteristics between the concentric and eccen-
tric stent expansion subgroup of PES in the POET trial; the
concentric group of PES had a relatively higher percentage
of diabetic patients (36% versus 24%, p = 0.107), smaller
mean RVD (2.83 versus 2.97 mm, p= 0.067), smaller MSA
(5.87 versus 6.36 mm
2, p= 0.065), and higher percentage of
lesions with final MSA < 5 mm
2 (28 versus 18%, p= 0.072).
These characteristics are generally considered important
predictors of restenosis.
12,13 Therefore, we believe the eccen-
tricity of stent expansion has no impact on neointimal
growth and clinical outcomes in both SES and PES. 
Although the local IVUS parameters like SE should not
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Table 4.Clinical Outcomes of Each Stent Group According to the Eccentricity of Stents 
SES (n = 108) PES (n = 125)
SE-NIH
Concentric Eccentric
pvalue
Concentric Eccentric 
pvalue
(n = 59) (n = 49) (n = 71) (n = 54)
Death, n (%) 0 (0) 0 (0) 1.000  0 (0) 0 (0) 1.000 
MI, n (%) 0 (0) 0 (0) 1.000  0 (0)  1 (2)  0.432 
TLR, n (%) 3 (5)  2 (4)  1.000 11 (14) 6 (11) 0.638
ST, n (%) 0 (0) 0 (0) 1.000  0 (0) 3 (4) 0.185
SE-MSA
Concentric Eccentric 
pvalue
Concentric Eccentric 
pvalue
(n = 63) (n = 45) (n = 73) (n = 52)
Death, n (%) 0 (0) 0 (0) 1.000  0 (0) 0 (0) 1.000 
MI, n (%) 0 (0) 0 (0) 1.000  0 (0)  1 (2)  0.416 
TLR, n (%) 4 (6)  1 (2)  0.399  12 (16) 5 (10) 0.245 
ST, n (%) 0 (0) 0 (0) 1.000  2 (3) 1 (2) 1.000 
SE-mean
Concentric Eccentric 
pvalue
Concentric Eccentric 
pvalue
(n = 63) (n = 45) (n = 67) (n = 58)
Death, n (%) 0 (0) 0 (0) 1.000  0 (0) 0 (0) 1.000 
MI, n (%) 0 (0) 0 (0) 1.000  0 (0)  1 (2)  0.464 
TLR, n (%) 3 (5)  2 (4)  1.000 12 (18) 5 (9) 0.091
ST, n (%) 0 (0) 0 (0) 1.000  0 (0) 3 (4) 0.213
Values are presented as numbers (percentages).
SES, sirolimus-eluting stents; PES, paclitaxel-eluting stents; SE, stent eccentricity; NIH, neointimal hyperplasia; MI, myocardial infarction; TLR, target-lesion
revascularization; ST, stent thrombosis; MSA, minimal stent area.be the main predictors for restenosis in DES ear, we should
not outlook the usefulness of these associated IVUS para-
meters, because it is almost certain that asymmetric stent
expansion in DES has caused the uneven diffusion of the
drug into the arterial wall.
3,4 But, DES eccentricity, only
calculated as the ratio of minimum and maximum stent
diameter, had no further impact on neointimal growth in
spite of the various determinations in SE. Rather, from the
recent IVUS studies, the parameters such as strut distribu-
tion or maximum interstrut angle on each slice has been
more heightened as the powerful IVUS predictor for res-
tenosis.
14-16 Therefore, the parameters associated with strut
distribution, considered to be the more detailed and com-
plex predictor than SE for restenosis, would be more import-
antly regarded as the IVUS predictors for restenosis. 
Study limitations
This study has several limitations. First, most patients en-
rolled in the POET were dilated up to 20 atm until the Multi-
center Ultrasound Stenting in Coronary Study (MUSIC)
criteria were met.
8 Due to this strategy, our study cases
might show relatively more concentrically expanded
tendencies, compared with those of real world practices.
These effects might influence SE and its clinical signifi-
cance. However, recently, postdilation with high pressure
is becoming more common for the acquisition of complete
opposition and larger stent area. Second, baseline clinical,
angiographic, or IVUS characteristics between eccentric
and the concentric group were not controlled. In fact, it was
impossible to control the baseline characteristics of the
study groups based on the SE. Third, the interactions bet-
ween asymmetric stent expansion and plaque distribution
or type, including calcification, were not fully examined.
However, the diffuse or calcified lesions were excluded in
the POET trial. In addition, the analysis of the inter-correla-
tion between SE and MSA and the evaluation of peristent
segments were not performed. The fourth limitation of our
study was the possibility that limited resolution of IVUS
might have missed some important findings. A recent
study by follow-up optical coherence tomography (OCT),
showing a higher resolution than IVUS, has shown that SE
may be associated with thrombus formation after SES
implantation.
17 Therefore, we should await the future result
of OCT studies regarding the expansion of DES.
18 Fifth,
for the definition of the eccentric expanded group, we used
mean SE. However, until now there has been no definitive
validated study for the cut off value of SE including mean
SE to define eccentric stent expansion. Finally, the stent
platforms used in this study are not currently available. PES
and SES in our study had previous stent platforms, which
were not different with currently available ones, Taxus
liberte
TM or Cypher Select
TM. The new platforms of PES or
SES could have a different influence on the current results
of our study. 
In conclusion, this study demonstrated that there were
no consistent correlations between various SE parameters
and neointimal growth. The asymmetric stent expansion of
both SES and PES might not affect the NIH and clinical
outcomes. 
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